Tisch Cancer Institute
The mission of The Tisch Cancer Institute (TCI), under the leadership of Dr. Steven Burakoff, is to build upon Mount Sinai Health System’s history of medical breakthroughs to offer new hope for those living with or at risk for cancer. The dedicated TCI team of basic science and clinical faculty are investigating the mechanisms behind the differentiation and growth of cancer cells and working to move discoveries quickly into therapeutic treatments. Institute members span across multiple departments in the medical center and work in multidisciplinary research programs such as Cancer Immunology, Cancer Mechanisms, Liver Cancer, Malignant Hematopoiesis and Cancer Prevention and Control. To facilitate pertinent clinical research, the Tisch Cancer Institute provides oversight of all clinical trials through its Protocol Review and Monitoring Committee and its centralized database of clinical trial protocols and enrollments. As of October 2013, cancer grant awards exceeded $45 million in direct costs, and in 2013, there were 129 open therapeutic clinical trials that enrolled a total of 286 new patients.
As part of its mission, the Tisch Cancer Institute supports several Shared Resources and Facilities dedicated for cancer researchers. These include three clinical resources: Cancer Clinical Trials Office, Cancer Biostatistics, and the Cancer Biorepository (in collaboration with the Department of Pathology), as well as many basic sciences resources: Flow Cytometry, Mouse Genetics, Microscopy, Immune Monitoring Core, and the Vaccine Core. In addition, the TCI provides competitive Research Awards to both basic, clinical, and population cancer scientists to facilitate new insights into cancer biology, prevention and treatment.
For more information:
Last update: May 20, 2014
Tisch Cancer Institute [PDF]